Abstract:A panel of experts recently completed updating the European Guidelines for the use of Ultrasound Contrast Agents. It is due to be published in early 2008 and updates and extends the 2004 Guidelines, which covered only the liver. The new liver section, which includes the use of USCM in interstitial ablation, incorporates the recent Barcelona guidelines for management of focal lesions discovered during ultrasound surveillance in cirrhotic patients. Though focussed on SonoVue, it forms a useful framework for a general discussion of this topic. It also covers clinically established uses in the kidneys and pancreas, in abdominal trauma, in vesico-ureteric reflux and in transcranial studies. The liver section of the guidelines opens with a rationale for beginning with characterisation of focal lesions rather than their detection, as may seem logical. This points up a fundamental awkwardness of the way USCM work in the liver: the initial arterial phase is particularly useful for differentiating between various focal lesions, while the late (sinusoidal) phase is critical for determining the malignant nature of solid liver lesions. Benign lesions such as haemangiomas and focal nodular hyperplasia have a rich arterial supply and often enhance early in the arterial phase. In haemangiomas, the blood enters the lakes that constitute the abnormality at the periphery of the lesion, giving rise to peripheral nodular enhancement. From here, it percolates towards the centre of the haemangioma, usually fairly slowly, taking up to five minutes to fill completely. At this stage, the lesion disappears as it matches the intensity of the enhanced liver parenchyma, though the process is incomplete in haemangiomas that contain thrombus, usually larger lesions. Thus, delayed scanning is required to confirm that the lesion has disappeared or at least become smaller. FNHs also have an arterial supply via one or several tortuous feeding vessels. However, the flow pattern is distinctive, arriving first at the centre of the lesion and filing it in a centrifugal fashion, often forming a spoke wheel pattern. The enhancement is often intense and very rapid (the “light bulb sign”) and so the early images after arrival of the contrast are critical; the study should be recorded so that these early frames can be reviewed, if necessary in slow motion, to allow the characteristic pattern to be recognised. In the late phase, FNHs disappear as the liver enhancement matches the enhancement in the lesion. In around a quarter of cases, the central scar becomes visible in this phase as a stellate central filling defect. For both lesions, these features carry the same confidence as the equivalent CT or MR haemodynamic findings and do not require further investigation when they are typical, as is the case in around 75% of cases. Atypical cases, which amount to 5 or 10%, require further investigation. Other lesions with diagnostic haemodynamic patterns are focal fatty sparing and change as well as regenerating nodules: they have normal haemodynamics and so behave in exactly the same way as the surrounding liver, disappearing in the late phase. Hepatic adenomas seem to have a variety of patterns, but experience with them is still limited, as it is for other uncommon focal lesions such as granulomas and peliosis.

Contrast-enhanced ultrasound in focal liver lesions: summarization of a series experience with 1015 cases referred to European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines

[Application Value of Contrast-Enhanced Ultrasonography for Assessing the High-Risk Population of Hepatic Malignant Tumor].

Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid

Clinical Value of Contrast-Enhanced Ultrasonography in the Characterization of Focal Liver Lesions: a Prospective Multicenter Trial.

Contrast enhanced ultrasound (CEUS) imaging of solid benign focal liver lesions.

Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines

Characterization of Focal Liver Lesions Indistinctive on B Mode Ultrasound: Benefits of Contrast-Enhanced Ultrasound

Clinical application of contrast-enhanced ultrasonography for malignant hepatic lesions undetected on conventional ultrasound

Focal Liver Lesions - Can Sonovue-Enhanced Ultrasound Be Used To Differentiate Malignant From Benign Lesions?

Comparison Of Contrast-Enhanced Ultrasound And Contrast-Enhanced Helical Ct In The Diagnosis Of High Echo-Level Small Focal Liver Lesions

Comparison of Contrast‐enhanced Ultrasonography with Virtual Touch Tissue Quantification in the Evaluation of Focal Liver Lesions

The value of contrast-enhanced ultrasound in the diagnosis of focal liver lesion in the transplanted liver

Application of Diagnosis of Abdominal Disease with Contrast-Enhanced Ultrasonograph

Clinical value of contrast-enhanced ultrasound versus conventional ultrasound in biopsy of focal liver lesions

Comments and illustrations of the WFUMB CEUS liver guidelines: Rare benign focal liver lesion, part I

Shear-wave elastography combined with contrast-enhanced ultrasound algorithm for noninvasive characterization of focal liver lesions

Contrast-enhanced ultrasonography in the characterization of focal liver lesions before microwave ablation therapy

- 32S 2-1 9 th US Contrast The Diagnosis of Liver Tumours with Ultrasound Contrast

Usefulness of the Contrast‐Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Focal Liver Lesions by Inexperienced Radiologists

The Study on Contrast Enhanced Ultrasonography in the Evaluating Therapeutic Response of Hepatic Malignancies Treated with Radiofrequency Ablation

Liver Tumor Characterization – Comments and Illustrations Regarding Guidelines